[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"S.LAB (SOLOWAYS)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":207},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,74,102,129,155,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100583519","study-of-the-safety-and-efficacy-of-natural-genome-reconstruction-technology-of-hematopoietic-stem-cells-in-adult-patients-100583519",false,"NCT06877377","Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patients","A Pilot Randomized, Blinded, Placebo-controlled Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patients","Inclusion Criteria:\n\n* . Men and women aged 45 to 65 years inclusive (optimal age range for a pilot study of the effect on aging processes).\n* Confirmed absence of serious chronic diseases in the decompensation stage (based on the results of a standard clinical and laboratory examination).\n* No history of malignant neoplasms over the past 5 years. Written informed consent to participate in the study. Willingness to comply with the study protocol, including attending all scheduled visits and undergoing the required diagnostic procedures.\n\nExclusion Criteria:\n\n* Pregnancy, lactation, or planning a pregnancy during the study.\n* The presence of immunodeficiency states (HIV infection, severe autoimmune diseases, etc.) in the acute stage.\n* Decompensated cardiovascular, hepatic, renal pathologies (a conclusion from a therapist or a specialized specialist is required).\n* Take immunosuppressants, corticosteroids or chemotherapeutic drugs within 3 months before screening.\n* Alcohol or drug addiction, confirmed by medical documents or identified during screening.\n* Participation in other clinical trials 30 days before inclusion or planned participation during this study.\n* Observation plan, duration of Follow-Up and number of visits",true,"ALL","45 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pilot randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of the hDNAgr technology aimed at natural genome reconstruction in hematopoietic stem cells in adults aged 45-65. The study hypothesizes that administering fragmented therapeutic double-stranded DNA will safely correct localized genomic damage-including telomere elongation-enhance hematopoietic function by restoring polyclonality and increasing reparative potential, and ultimately rejuvenate blood and bone marrow to potentially lower the patient's biological age. The primary endpoint is safety and tolerability, assessed by the frequency and severity of adverse events, while secondary endpoints focus on telomere length, hematological parameters, aging and inflammation biomarkers, functional health measures, and preliminary biological age evaluations. Sixty participants (30 in the hDNAgr group and 30 receiving placebo) will be observed over a 6-month period with multiple scheduled visits.",[28],"Aging",[30,31],"DNAgr-technology","haemopoesis","NOT_YET_RECRUITING","2025-07-18",{"date":35,"type":36},"2025-07-20","ACTUAL",{"date":38,"type":22},"2025-09-01",{"date":40,"type":22},"2026-03-01",{"name":42,"class":43},"S.LAB (SOLOWAYS)","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100549442","phase-3-clinical-trial-protocol-randomized-placebo-controlled-pilot-study-of-gcmaf-soloways-tm-in-patients-with-metastatic-breast-cancer-100549442","NCT06434077","Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer","Inclusion Criteria:\n\n* Diagnosis:\n\n  * Histologically or cytologically confirmed metastatic breast cancer.\n  * Evidence of metastatic disease, confirmed by imaging studies (CT, MRI, or PET scans) and\u002For biopsy. 2. Prior Treatment:\n  * Patients must have completed at least one line of systemic therapy (e.g., chemotherapy, hormone therapy, targeted therapy) for metastatic breast cancer.\n  * A minimum of 4 weeks must have elapsed since the last chemotherapy, targeted therapy, or radiotherapy before starting the study treatment. 3. Age:\n  * Female patients aged 18 to 70 years. 4. Performance Status:\n  * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 5. Life Expectancy:\n  * Estimated life expectancy of at least 6 months. 6. Laboratory Values:\n  * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL, platelets ≥ 100 x 10\\^9\u002FL, and hemoglobin ≥ 9 g\u002FdL.\n  * Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver metastases).\n  * Adequate renal function: Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m\\^2 (calculated using the Cockcroft-Gault formula). 7. Contraception:\n  * Women of childbearing potential must agree to use effective contraception (e.g., hormonal contraceptives, intrauterine device, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of study treatment. 8. Informed Consent:\n  * Ability to understand and willingness to sign a written informed consent document.\n\n    9\\. Compliance:\n  * Willingness and ability to comply with the study protocol, including scheduled visits, treatment plans, laboratory tests, and other study procedures. 10. Nagalase Levels: • Elevated serum nagalase levels above the normal range, indicating active tumor burden.\n\nExclusion Criteria:\n\n* Concurrent Malignancies:\n\n  * Presence of other active malignancies (excluding adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix). 2. Severe Comorbid Conditions:\n  * Severe uncontrolled concurrent illness, such as significant cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction), severe pulmonary conditions (e.g., uncontrolled asthma, chronic obstructive pulmonary disease), or active infections requiring systemic therapy. 3. Pregnancy and Lactation:\n  * Pregnant or breastfeeding women. 4. Previous GcMAF Treatment:\n  * Previous treatment with GcMAF. 5. Allergies and Sensitivities:\n  * Known hypersensitivity to any component of the study drug or its formulation.","FEMALE","18 Years","80 Years",{"count":21,"type":22},[55],"PHASE3","This randomized, double-blind, placebo-controlled pilot study aims to evaluate the efficacy and safety of GcMAF in reducing nagalase levels and improving clinical outcomes in female patients with metastatic breast cancer over six months. Sixty patients will be randomized into two groups receiving either weekly GcMAF or placebo injections. The primary endpoint is the change in serum nagalase levels from baseline to six months. Secondary endpoints include clinical status, quality of life, adverse effects, and markers of inflammation and immune activity. Tumor response will be assessed using RECIST criteria, and quality of life will be measured with the EORTC QLQ-C30 questionnaire. Immune and inflammation markers will be evaluated using flow cytometry and ELISA. Adverse events will be monitored and categorized according to severity. Inclusion criteria include confirmed metastatic breast cancer, completion of one line of systemic therapy, adequate organ function, and elevated serum nagalase levels. The study will involve baseline measurements, monthly assessments, and final evaluations to compare changes in nagalase levels and other clinical outcomes between the GcMAF and placebo groups.",[58],"Breast Cancer",[60,61,62,63,64],"Metastatic Breast Cancer","GcMAF (Gc Macrophage Activating Factor)","Nagalase","Inflammation Markers","Response Evaluation Criteria in Solid Tumors","2025-06-19",{"date":67,"type":36},"2025-06-22",{"date":69,"type":22},"2025-08-20",{"date":71,"type":22},"2026-12-20",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100536418","evaluation-of-a-genetically-determined-personalized-approach-in-prescribing-biologically-active-substances-in-patients-with-elevated-blood-homocysteine-levels-100536418","NCT06264570","Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.","Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels, Prospective,Double-blind Randomised Trial.","PERBIO-HC","Inclusion Criteria:\n\n* Increased homocysteine level above 15 µmol\u002Fl;\n* Increased LDL level \\>=1.4 mmol\u002Fl.;\n* Absence of taking medications or any other products that may affect homocysteine levels in the blood for at least 1 month before enrollment in the study;\n\nExclusion Criteria:\n\n* Individual intolerance to the components of the substance;\n* Pregnancy or breastfeeding;\n* Severe concomitant disease requiring constant monitoring (estimated survival less than 1 year);\n* Taking dietary supplements or medications containing one of the components: dietary supplements for at least 3 months before inclusion in the study.",{"count":83,"type":22},111,[25],"The clinical trial assesses the effectiveness and safety of a genetically-determined personalized approach to prescribing bioactive substances in patients with elevated blood homocysteine levels. Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular diseases (CVD), potentially exacerbating the effects of arterial hypertension and high cholesterol levels, increasing the risks of heart disease, stroke, and venous thrombosis. The trial aims to reduce plasma homocysteine levels to normal values (\\\u003C15 µmol\u002FL) through a pilot, single-center, prospective, double-blind, placebo-controlled study. The study will involve a 6-month observation period with visits at 1, 3, and 6 months, assessing the efficacy of two composite bioactive substances not considered medicinal drugs. The primary endpoint is the reduction of homocysteine levels in patients with elevated levels, while secondary endpoints include lowering very low-density lipoprotein levels, absence of anxiety and depression (using the Spielberg Anxiety Scale), and the occurrence of major cardiovascular events. The sample size is planned for 111 patients across three groups, with a 1:1:2 distribution, considering a 40% reduction in homocysteine levels in the treated group and 5% in the control group, aiming for an 80% power and a 0.05 alpha. Inclusion criteria include adults aged 18-80 with elevated homocysteine (\\>15 µmol\u002FL) and LDL cholesterol levels (≥1.4 mmol\u002FL), without taking any substances that could influence homocysteine levels for at least one month prior. The trial will also conduct an interim analysis after enrolling 55 patients, using statistical analysis to evaluate the results.",[87],"Hyperhomocysteinemia",[87,89,90,91,92],"Cardiovascular diseases","Bioactive substances","Genetically-determined approach","Nutrigenomics","RECRUITING","2025-06-06",{"date":96,"type":36},"2025-06-08",{"date":98,"type":36},"2023-10-23",{"date":100,"type":22},"2026-10-30",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":73},"100536790","a-combination-of-ibuprofen-with-curcumin-covered-with-liquorice-root-supplementation-in-the-management-of-postoperative-dental-pain-in-adults-100536790","NCT06269406","A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults","A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults, Randomized, Double- Blind, Parallel-Group, Placebo-Controlled Study","ICLID","Inclusion Criteria:\n\n* Removal of 2 to 4 impacted third molars\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Ibuprofen contraindications.\n* Allergy to any of the intervention components.","85 Years",{"count":112,"type":22},264,[25],"Dental pain, a common issue in stomatology, requires a multifaceted treatment approach. This study explores the efficacy of combining Ibuprofen with curcumin and liquorice root supplements for managing postoperative dental pain. Curcumin, known for its antioxidant and anti-inflammatory properties, along with liquorice root, may enhance pain relief beyond conventional NSAIDs like Ibuprofen. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety and effectiveness of this combination therapy in adults undergoing the removal of impacted third molars. Participants, aged 18-85, were divided into groups receiving different doses of Ibuprofen and curcumin with liquorice root, compared to a control group receiving Ibuprofen and placebo. The primary outcome is the sum of pain intensity differences over 8 hours, with secondary outcomes including total pain relief and the occurrence of any adverse events. The anticipated sample size, considering a 20% dropout rate, is 264 participants, ensuring the study is powered to detect significant differences in pain management efficacy.",[116],"Dental Pain",[118,119,120,121,122],"Postoperative Dental Pain","Curcumin and Licorice Root","Ibuprofen","Anti-inflammatory Properties","molars",{"date":96,"type":36},{"date":125,"type":22},"2025-07-28",{"date":127,"type":22},"2025-09-28",{"name":42,"class":43},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":110,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":73},"100536416","trial-to-evaluate-the-efficacy-of-a-zinc-selenium-and-l-tyrosine-supplement-in-the-prevention-of-thyrotoxicosis-in-subjects-with-r25191ga-sepp1-polymorphism-100536416","NCT06264544","Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G\u002FA SEPP1 Polymorphism","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G\u002FA SEPP1 Polymorphism","ZEST-PREP","Inclusion Criteria:\n\n* Confirmed presence of one or more specified gene polymorphism r25191G\u002FA SEPP1\n* TPOAb levels \\> 300 IU\u002FmL\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years and \\>85\n* Pregnant or breastfeeding woman\n* Subjects with allergy to any of the supplementation component patients with any established diagnosis of thyroid disease",{"count":138,"type":22},150,[25],"This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G\u002FA SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant\u002Fbreastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. With an estimated sample size of 150 participants per group, accounting for a 20% dropout rate, the trial seeks to demonstrate the supplement's potential in reducing thyrotoxicosis risk through a genetically-informed approach.",[142],"Thyrotoxicosis",[144,145,146,147,92,148],"Thyrotoxicosis Prevention","SEPP1 Polymorphism","Zinc, Selenium, and L-Tyrosine Supplementation","supplementation","Thyroid Peroxidase Antibodies (TPOAb)",{"date":96,"type":36},{"date":151,"type":22},"2025-07-30",{"date":153,"type":22},"2025-12-30",{"name":42,"class":43},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":162,"maxAge":19,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":73},"100586177","comparative-efficacy-of-metformin-and-berberine-among-tcf7l2-rs7903146-tt-vs-cc-genotype-carriers-with-type-2-diabetes-100586177","NCT06911983","Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabetes","Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabetes: A Pilot Randomized Clinical Study","Inclusion Criteria:\n\n* Adults aged 30-65 years;\n* Newly diagnosed T2DM ≤1 year;\n* Baseline HbA1c: 7.0-9.0% (53-75 mmol\u002Fmol);\n* No prior use of antihyperglycemic agents or ≤4 weeks of usage;\n* Willing to sign informed consent and undergo TCF7L2 genotyping;\n* TT or CC genotype (rs7903146)\n\nExclusion Criteria:\n\n* Severe comorbidities (hepatic, renal, cardiac dysfunction);\n* Pregnancy or lactation;\n* Known allergy or intolerance to metformin or berberine;\n* Participation in another clinical trial within the last 3 months;\n* TC genotype (excluded).","30 Years",{"count":21,"type":22},[25],"This pilot 12-week randomized open-label study compares metformin and berberine in newly diagnosed type 2 diabetes patients stratified by the TCF7L2 (rs7903146) genotype (TT vs. CC). The primary goal is to assess changes in HbA1c between metformin and berberine treated groups within each genotype. Secondary outcomes include fasting and postprandial glucose, insulin levels, HOMA-IR, body weight\u002FBMI, lipid profile and adverse events.\n\nThe central hypothesis is that berberine, through its additional effect on TCF7L2-linked pathways, will provide superior glycemic control in high-risk TT carriers compared to metformin, whereas both treatments will yield comparable results in CC carriers. By enrolling only TT and CC genotypes, this study aims to estimate effect sizes and feasibility, guiding a future, larger-scale trial on genotype-tailored diabetes therapies.",[167],"Diabetes Mellitis",[169,170,171,172],"genetics","polymorphysm","supplements","berberine","2025-04-17",{"date":175,"type":36},"2025-04-20",{"date":177,"type":22},"2025-07-01",{"date":40,"type":22},{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":73},"100582795","a-pilot-study-of-vitamin-k2-menaquinone-7-soloways--in-patients-with-osteopeniaosteoporosis-carrying-a-vdr-gene-variant-100582795","NCT06867952","A Pilot Study of Vitamin K2 (Menaquinone-7, Soloways ™) in Patients With Osteopenia\u002FOsteoporosis Carrying a VDR Gene Variant","Inclusion Criteria:\n\n* Adults aged 40-75 years with a confirmed DXA-based diagnosis of osteopenia or osteoporosis (T-score ≤ -1.0).\n* Stable dietary habits and willingness to maintain current exercise regimen throughout the study.\n* Willingness to undergo genotyping for the VDR variant. For the VDR Variant Cohort: confirmed homozygous \"unfavorable\" variant (e.g., BsmI or ApaI).\n* For the Non-Variant Cohort: confirmed absence of the \"unfavorable\" allele (wild-type).\n\nExclusion Criteria:\n\n* Current or recent (last 3 months) use of high-dose bisphosphonates, anabolic agents (e.g., teriparatide), or selective estrogen receptor modulators (SERMs). Known allergy or hypersensitivity to vitamin K or vitamin D supplements.\n* Severe renal or hepatic dysfunction, uncontrolled hyperthyroidism, or other significant comorbidities that could confound bone metabolism assessments.\n* Pregnancy or breastfeeding.\n* Inability or unwillingness to provide informed consent or to comply with study procedures.","40 Years","75 Years",{"count":189,"type":22},40,[25],"This pilot, genotype-stratified clinical trial aims to evaluate the safety and preliminary efficacy of vitamin K2 (menaquinone-7, MK-7) supplementation in patients with low bone mineral density (osteopenia or osteoporosis) who carry a specific \"unfavorable\" variant in the vitamin D receptor (VDR) gene (e.g., BsmI or ApaI polymorphisms). The trial will compare improvements in bone health and related biomarkers between two cohorts: (1) homozygous carriers of the VDR variant and (2) non-variant carriers (wild-type). Investigators hypothesize that MK-7 supplementation will lead to greater improvements in bone mineral density (BMD) and bone turnover markers in the homozygous variant group due to their potentially reduced baseline response to vitamin D signaling.",[193,194],"Osteoporosis","Osteopenia",[194,193,196,197,198],"Supplements","Vitamin K2","Vitamin D","2025-03-14",{"date":201,"type":36},"2025-03-17",{"date":203,"type":36},"2024-05-03",{"date":205,"type":22},"2026-03-03",{"name":42,"class":43},""]